Icon Plc $ICLR Shares Purchased by Annis Gardner Whiting Capital Advisors LLC

Annis Gardner Whiting Capital Advisors LLC increased its position in shares of Icon Plc (NASDAQ:ICLR) by 17,066.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,605 shares of the medical research company’s stock after buying an additional 3,584 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Icon were worth $631,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership boosted its stake in shares of Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after acquiring an additional 2,893,946 shares in the last quarter. Harris Associates L P acquired a new position in Icon in the 2nd quarter worth about $238,256,000. Norges Bank acquired a new position in Icon in the 2nd quarter worth about $158,639,000. 1832 Asset Management L.P. boosted its position in Icon by 587.9% during the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock worth $167,461,000 after purchasing an additional 983,950 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Icon in the second quarter valued at approximately $94,814,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ICLR shares. TD Cowen upped their target price on Icon from $172.00 to $183.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Mizuho set a $216.00 price objective on shares of Icon in a research report on Friday, January 9th. BMO Capital Markets began coverage on shares of Icon in a report on Thursday, November 13th. They set a “market perform” rating and a $175.00 price objective on the stock. Barclays boosted their target price on shares of Icon from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, UBS Group set a $220.00 price target on shares of Icon in a research note on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $200.60.

Icon Stock Performance

Shares of Icon stock opened at $186.32 on Thursday. The business’s 50 day moving average price is $183.09 and its 200 day moving average price is $176.12. The company has a market cap of $15.05 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 3.97 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a one year low of $125.10 and a one year high of $211.00.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.